Skip to content

The Effect of Sodium Alginate on Appetite Sensation

The Effect of Sodium Alginate Containing Beverage on Appetite and Body Weight Regulation

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01101633
Acronym
B247Algobes
Enrollment
20
Registered
2010-04-12
Start date
2009-02-28
Completion date
2009-10-31
Last updated
2010-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Overweight

Keywords

Appetite, Energy intake, gastric emptying, well being, Body weight

Brief summary

The aim of the study is to investigate the effects of a low-calorie alginate containing fruit flavored beverage on appetite and body weight development.

Detailed description

The project consists of two different studies: Study I: A randomised controled meal test study aimed at studying the acute effect of the alginate-containing beverage on appetite sensation and spontaneous calorie intake (and safety i.e. nausea, well-being etc) in normal to overweight healthy subjects. Here, a placebo beverage or the alginate-containing beverage will be administered as a pre-load before a standardised breakfast meal. Subjective appetite sensation will be measured with Visual Analogue Scale (VAS) every 30 minutes four up to 5 hours. An additional beverage will be administered prior to an ad libitum lunch meal, where spontaneous water and energy intake will be registered. Study II: Secondly the aim is to study the effects of a daily intake of a placebo or alginate-containing beverage on body weight and composition in a randomised parallel intervention study of 12 weeks duration. A total of app. 50 obese healthy adults will receive a hypocaloric diet and be randomised to consume either placebo or alginate-containing beverage before each of the three main meals every day. The development in body weight and composition and blood pressure will be monitored and blood samples will be analysed for markers related to the risk of CVD and type 2 diabetes.

Interventions

DIETARY_SUPPLEMENTAlginate

a 500 ml alginate beverage per meal test

DIETARY_SUPPLEMENTPlacebo

a 500 ml placebo beverage per meal test

Sponsors

SBiotek
CollaboratorUNKNOWN
University of Copenhagen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy men and women * Normal to slight overweight (BMI: 22-28 kg/m2) * 20-45 years of age

Exclusion criteria

* Smoking * Daily medicine use (oral contraceptives excluded) * Use of dietary supplements * Blood donation 3 months prior to the study * Hb\<7.5 mmol/l * Chronic illnesses such as hyperlipidemia, diabetes and inflammatory diseases * Pregnancy or breastfeeding * Elite athletes (\>10 hours hard exercise/week) * Vegetarians

Design outcomes

Primary

MeasureTime frame
appetite sensation5 hours

Secondary

MeasureTime frame
Plasma insulin and glucose level5 hours
Well being and adverse events5 hours
gastric emptying5 hours
spontaneous calorie intake5 hours

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026